制药：从标准型到专业型胶囊规格，明胶空心胶囊、HPMC、吸入型和阴道型规格，专为满足各种治疗需求而设计。
营养保健品：面向消费者的营养保健品规格。为追求差异化的膳食补充剂生产商量身定制的胶囊和品牌原料。
胶囊
Oral delivery of glucagon-like peptide-1 (GLP-1) peptides has the potential to improve patient convenience and adherence, but gastrointestinal degradation and limited intestinal absorption remain significant challenges. In this newly published study, researchers at Lonza Capsugel developed and evaluated a proof-of-concept oral delivery platform combining hydrophobic ion pairing (HIP), lipid-based formulation (LBF), and enteric capsule technology.
Targeting the distal small intestine, specifically the terminal ileum, remains one of the greatest challenges in oral drug delivery.
Innovation in oral formulation technologies has opened new avenues for the lifecycle management and patent protection of biologics. Technologies such as SNAC, LBFs, HIPs, permeation enhancers, and Capsugel® Enprotect® capsules are now enabling the oral delivery of biologics. This step forward has the potential to benefit patients (with increased choice and accessibility), the healthcare system (with reduced staff workload and waste), and pharmaceutical companies (with extended patent protections).
The success and adoption of oral GLP-1 RAs mark a shift in biologic drug delivery. Technologies such as permeation enhancers, LBFs, and enteric protection have made the oral delivery of biologics a reality. By combining biologic level efficacy with the convenience and reach of oral dosing, formulators can open the door to more patient centric therapies, earlier intervention, and broader access, setting the foundation for a future in which oral biologics are no longer the exception, but the expectation.
Healthcare systems are facing increasing pressure as record demand, an aging population, the burden of chronic disease, and economic inflation challenge clinics, hospitals, and healthcare professionals to adequately keep up.1,2 Workforce supply shortages and tight healthcare budgets, especially since COVID-19, contribute to significant capacity issues across the healthcare system, e.g. poor access to appointments across primary and secondary care and discharge delays
Meeting consumers’ needs is the first priority for any successful business. For over-the-counter (OTC) medications and supplements, oral dosage forms have long been the cornerstone of self-administration. Traditionally, capsules have been composed of gelatin derived from cattle or pig bones and hides.1 Gelatin produces a high-gloss capsule that can be manufactured in many colors, offering attractive product packaging and easy swallowability—both positives for consumers. However, many consumers are now more concerned about the ethics of what they purchase and consume.2 In a recent survey, 70% of consumers said they believe it’s “important” or “very important” that the health and wellness products they buy are also eco-friendly and/or ethically produced, and 71% are willing to pay more for wellness products with these attributes.
The capsule market is shifting due to the growing importance of ethics and sustainability in driving consumer behavior. The ethical spending market has shown year-on-year growth since 1999, and spending on ethical products grew by over 20% in 2022 alone.
Maximizing Productivity in Vegan and Vegetarian Capsules Filling
实现具有口服生物利用度的生物制剂递送，需要多个领域的专业知识。Lonza Capsugel scientists and technologists are dedicated to working with you to optimize every aspect of your formulation, from concept to commercialization, to deliver a viable oral dosage form.
Biological therapies have transformed the treatment of chronic and complex diseases, yet their impact is often limited by the need for parenteral administration. Oral delivery of biologics represents a major opportunity to improve patient experience, adherence, and healthcare efficiency, but achieving it has historically been constrained by poor stability and low bioavailability of the API in the gastrointestinal (GI) tract.
在我们最新的播客中，Lonza Capsugel 的 Frank Romanski 探讨了患者偏好如何重塑开发策略。
多年来，生物制剂的口服给药一直被认为不切实际。但是如果问题不在于给药途径本身，而在于我们采用的方法是否得当？
Understanding patient attitudes and preferences has become an essential part of modern therapeutic decision making. The effectiveness of therapies doesn’t solely depend on the action of the medication itself, but also on additional factors, e.g. how it is formulated and administered.
Pre-clinical studies are essential for evaluating the safety, pharmacokinetics, and efficacy of drug candidates before entering human trials.
Poster presentation delivered at the Controlled Release Society (CRS) Annual Meeting, 2025.
At the Innovaform® Accelerator, we’re commited to advancing drug delivery through collaboration and cutting-edge science.
Explore how Lonza’s advanced polymer science and capsule manufacturing capabilities - Capsugel® Enprotect® - have led to a breakthrough in enteric protection.
Unlocking the full potential of many therapies hinges on effective absorption in the lower GI tract. Yet, delivering fragile APIs to the right location is no small feat.
The lower gastrointestinal tract is critical for enhancing bioavailability and drug absorption, directly influencing therapeutic efficacy.
Enteric capsules have many applications. Their principal purpose is to prevent the release of active pharmaceutical ingredients (APIs) in the stomach and to avoid them being exposed to gastric acid.
The lower GI tract plays an important role in how well drugs are absorbed and utilized by the body. But delivering sensitive APIs to this region—especially those vulnerable to acidic environments.
The lower gastro-intestinal tract plays an important role in optimizing bio-availability and drug absorption – and therefore the effectiveness of many therapies. But delivering sensitive APIs to the right location is a challenge. In a series of ‘real world’ questions, we explore the options and solutions when it comes to the targeted delivery of acid-sensitive APIs.
These findings confirm that Capsugel® Enprotect® capsules offer a robust, scalable, & patient-friendly alternative to traditional double-encapsulation methods
This downloadable summary features findings from a peer-reviewed study evaluating the in vivo performance of Capsugel® Enprotect® capsules
深入对比传统包衣方法与新型双层聚合物技术，例如 Capsugel® Enprotect® 胶囊所采用的技术
Discover how Capsugel® Enprotect® capsule’s bi-layered polymer technology enables targeted enteric delivery—without the need for post-filling coating.
本产品规格手册概述了 Capsugel® Enprotect® 胶囊。它详细说明了胶囊的组成、性能、溶解数据、崩解数据、尺寸、颜色选项和稳定性。
Capsugel® Enprotect® 是一种即用型肠溶胶囊，耐酸性高达 pH 6.0，无需填充后包衣。本科学宣传册提供了支持该胶囊性能的证据。
Capsule-based Dry Powder Inhaler (cDPI) represents a prominent solution in the inhalation therapy domain. This poster explores the influence of capsule type on cDPI performance.
Faecal microbiota transplantation (FMT) is a highly effective treatment for diseases where the intestinal microbiota is compromised, particularly Clostridioides difficile infection.
Across two days our program will include eight specialized topic areas diving into specific developments within the industry, from formulation & delivery
In this study, the performance of Capsugel® Enprotect® capsules was evaluated using the DGM-intestinal model after intake in fasted and fed state and compared to in vivo data.
Respiratory Drug Delivery is a premier, international conference series providing comprehensive coverage of all aspects of drug delivery to the lungs and nose.
This study shows that Capsugel® Enprotect® capsules are stable and compatible with standard FMT placebo formulation
2025 年 1 月 15 日，美国 FDA 宣布 FD&C 红色 3 号（赤藓红，E127）着色剂将不再获准用于食品和口服药物。
Aanchal Tomar Executive Director, Asia Pacific, Lonza CHI interview where she speaks about Lonza Capsules & Health Ingredients' strategic growth, challenges, and sustainability initiatives in the APAC market
Fecal Microbiota Transplant (FMT) oral delivery is a challenge. Today, fecal suspensions are concentrated, double-encapsulated in size 0 and 00 capsules and then stored at -80°C for 2 years.
Following a busy year for innovation in pharmaceutical manufacturing technologies – and many worthy nominees, we can now announce the grand winner of The Medicine Maker Innovation Awards.
Get more information about Capsugel® DBcaps® capsule with this FAQ.
Request a brochure or sample of Capsugel® Enprotect® Capsule - First of its kind enteric technology
The empty hard capsules are supplied as an excipient that is filled by pharmaceutical manufacturers with a variety of different formulations and products. To understand the potential variations of the empty hard capsules as an input parameter and its potential impact on the finished product quality, a study was performed investigating the critical quality parameters within and in between different batches of empty hard gelatin capsules. Hard capsules can be considered as a suitable excipient for product development using QbD principles.
This paper provides a technical review of formulation considerations relating to the use of gelatin Capsugel® DBcaps® capsules for clinical trials, as well as a list of published references.
